John C Lyons

US Patent:

6977247, Dec 20, 2005

Filed:

Feb 21, 2002

Appl. No.:

10/081974

Inventors:

Joseph Rubinfeld - Danville CA, US
Karl L. Mettinger - Berkeley CA, US
John Lyons - Moraga CA, US
Lawrence A. Romel - Oakland CA, US

Assignee:

SuperGen, Inc. - Dublin CA

International Classification:

A01N043/04
A01N043/42
A61K031/70
A61K031/44

US Classification:

514 50, 514 34, 514 49, 514256, 514283

Abstract:

A method is provided for treating a patient having a disease associated with undesirable or uncontrolled cell proliferation, the method comprising: administering to the patient a 20(S)-camptothecin for a period of time during which a pyrimidine base analog is not being administered to the patient; and administering a pyrimidine base analog to the patient.

US Patent:

6998391, Feb 14, 2006

Filed:

Jul 26, 2002

Appl. No.:

10/206854

Inventors:

John Lyons - Moraga CA, US
Joseph Rubinfeld - Danville CA, US

Assignee:

SuperGen.Inc. - Dublin CA

International Classification:

A61K 31/7072

US Classification:

514 49, 514 85, 514269, 5142345, 514300, 536 235, 536 231, 435 691, 435325, 530350, 424 45, 424450

Abstract:

Methods are provided for treating diseases associated with abnormal activity of kinases. The method comprises: administering a DNA methylation inhibitor to the patient in therapeutically effective amount; and administering a kinase inhibitor to the patient in therapeutically effective amount, such that the in vivo activity of the kinase is reduced relative to that prior to the treatment. The method can be used to treat cancer associated with abnormal activity of kinases such as phosphatidylinositol 3′-kinase (PI3K), protein kinases including serine/threonine kinases such as Raf kinases, protein kinase kinases such as MEK, and tyrosine kinases such as those in the epidermal growth factor receptor family (EGFR), platelet-derived growth factor receptor family (PDGFR), vascular endothelial growth factor receptor (VEGFR) family, nerve growth factor receptor family (NGFR), fibroblast growth factor receptor family (FGFR) insulin receptor family, ephrin receptor family, Met family, Ror family, c-kit family, Src family, Fes family, JAK family, Fak family, Btk family, Syk/ZAP-70 family, and Ab1 family.

US Patent:

7307071, Dec 11, 2007

Filed:

Dec 3, 2002

Appl. No.:

10/308721

Inventors:

John F. Lyons - Moraga CA, US
Gideon Bollag - Hercules CA, US

Assignee:

Onyx Pharmaceuticals, Inc - Emeryville CA

International Classification:

A61K 31/025
A61K 31/03
A61K 31/13
A61K 31/075
A61K 31/08
A61K 31/17
A61K 31/33

US Classification:

514183, 514588, 514591, 514596, 514597, 514619, 514620, 514647, 514660, 514670, 514672, 514673, 514716, 514717, 514718, 514719, 514721, 514722, 514747, 514749, 514751

Abstract:

Materials and methods for treating certain cancers are described, preferably cancers that result from the up-regulation of the RAF-MEK-ERK pathway, and more preferably chronic myelogenous leukemia, and which cancer is preferably resistant to the inhibition of the Bcr-Abl tyrosine kinase, imatinib.

US Patent:

20030147813, Aug 7, 2003

Filed:

Feb 7, 2002

Appl. No.:

10/071849

Inventors:

John Lyons - Moraga CA, US

International Classification:

A61K031/7072
A61L009/04
A61K009/127

US Classification:

424/045000, 514/049000, 424/450000

Abstract:

Methods, compositions and kits are provided for treating cancer associated with protein tyrosine kinase activity such as chronic myelogenous leukemia. In particular, a treatment method is provided comprising: administering to a patient having chronic myelogenous leukemia and a degree of resistance to imatinib mesylate, a therapeutically effective amount of a DNA methylation inhibitor which mitigates the imatinib mesylate resistance.

US Patent:

20050209186, Sep 22, 2005

Filed:

Dec 3, 2004

Appl. No.:

11/004665

Inventors:

John Lyons - Moraga CA, US

International Classification:

A61K031/7072

US Classification:

514049000

Abstract:

Methods, compositions and kits are provided for treating cancer associated with protein tyrosine kinase activity such as chronic myelogenous leukemia. In particular, a treatment method is provided comprising: administering to a patient having chronic myelogenous leukemia and a degree of resistance to imatinib mesylate, a therapeutically effective amount of a DNA methylation inhibitor which mitigates the imatinib mesylate resistance.

US Patent:

20060052334, Mar 9, 2006

Filed:

Sep 23, 2005

Appl. No.:

11/234865

Inventors:

Joseph Rubinfeld - Danville CA, US
Karl Mettinger - Berkeley CA, US
John Lyons - Moraga CA, US
Lawrence Romel - Oakland CA, US

International Classification:

A61K 31/7072
A61K 31/513
A61K 31/4745

US Classification:

514050000, 514269000, 514283000

Abstract:

A method is provided for treating a patient having a disease associated with undesirable or uncontrolled cell proliferation, the method comprising: administering to the patient a 20(S)-camptothecin for a period of time during which a pyrimidine base analog is not being administered to the patient; and administering a pyrimidine base analog to the patient.

US Patent:

20060140947, Jun 29, 2006

Filed:

Jul 13, 2005

Appl. No.:

11/181368

Inventors:

John Lyons - Moraga CA, US
Joseph Rubinfeld - Danville CA, US

International Classification:

A61K 48/00
A61K 31/7072
A61K 38/54
A61K 39/395

US Classification:

424145100, 514049000, 514044000

Abstract:

Methods are provided for treating diseases associated with abnormal activity of kinases. The method comprises: administering a DNA methylation inhibitor to the patient in therapeutically effective amount; and administering a kinase inhibitor to the patient in therapeutically effective amount, such that the in vivo activity of the kinase is reduced relative to that prior to the treatment. The method can be used to treat cancer associated with abnormal activity of kinases such as phosphatidylinositol 3′-kinase (PI3K), protein kinases including serine/threonine kinases such as Raf kinases, protein kinase kinases such as MEK, and tyrosine kinases such as those in the epidermal growth factor receptor family (EGFR), platelet-derived growth factor receptor family (PDGFR), vascular endothelial growth factor receptor (VEGFR) family, nerve growth factor receptor family (NGFR), fibroblast growth factor receptor family (FGFR) insulin receptor family, ephrin receptor family, Met family, Ror family, c-kit family, Src family, Fes family, JAK family, Fak family, Btk family, Syk/ZAP-70 family, and Abl family.

US Patent:

20180268939, Sep 20, 2018

Filed:

May 24, 2018

Appl. No.:

15/988086

Inventors:

- Menlo Park CA, US
David Penake - Menlo Park CA, US
John Lyons - Menlo Park CA, US
Kate Tully - Menlo Park CA, US
Katherine Waidner - Menlo Park CA, US

International Classification:

G16H 50/20
A61B 5/00
G16H 10/60

Abstract:

Devices, systems, and methods for use in managing patient treatments utilizing pharmaceutical or therapeutic compounds. Methods include accessing one or more fields of information relating to any of a patient, physician and drug treatment and relating the one or more fields, or combination thereof, to a particular attribute or outcome. By analyzing the one or more fields of data in relation to the attribute or outcome, the system determines suitability of an intervention(s) and tasks the intervention(s) to one or more entities to facilitate the desired attribute or outcome. In certain aspects, the system facilitates identification of complex relationships and trends between seemingly unrelated fields of information and outputs information for use in an intervention or various other purposes according to the attribute or outcome desired by the user.